WASHINGTON – State-licensed medical marijuana businesses now have something they have never had before: a live Drug Enforcement Administration portal and a defined federal registration path tied to their existing medical licenses.
The shift follows a new Justice Department and DEA rule placing two categories into Schedule III of the Controlled Substances Act: FDA-approved products containing marijuana, and marijuana products regulated under a qualifying state-issued medical marijuana license. For operators, that means the practical question is no longer whether Washington has created a pathway. It has. The question is whether a business qualifies, how quickly it should apply, and how much broader rescheduling politics could still change the landscape around it.
DEA’s new public-facing portal, available at mmapplication.diversion.dea.gov, appears to be the agency’s intake point for those applications. Public site routes include pages for registration instructions, self-registration, login, and intake, indicating the system is live for applicants rather than merely announced in theory.
The eligibility filter: Who can register?
Under the final order, a qualifying “state medical marijuana license” is one issued by a state, the District of Columbia or a U.S. territory authorizing the holder to manufacture, distribute, and/or dispense marijuana or marijuana-containing products for medical purposes.
The federal registration categories created in the order mirror those activities:
- Manufacturers may cultivate, produce, process, package, label and transfer marijuana or marijuana-containing products to registered manufacturers or distributors, subject to state-license limits.
- Distributors may receive marijuana or marijuana-containing products from registered manufacturers and transfer them to registered distributors or dispensers, again within state-license limits.
- Dispensers may dispense to individuals authorized by state law to possess marijuana or marijuana-containing products for medical purposes.
That means this is not a broad federal opening for every cannabis operator. Adult-use businesses are not covered unless they also hold qualifying medical authority, and even then the federal registration does not authorize non-medical activity.
The 60-day sprint: a step-by-step registration guide
Based on the final order and DEA’s public registration materials, the cleanest verified sequence for operators is:
1. Confirm that your business holds a qualifying state medical marijuana license. The federal pathway is tied directly to that license.
2. Match your activity to the correct federal registration type: manufacturer, distributor, dispenser, or more than one if your state-authorized business model spans multiple functions.
3. Access DEA’s dedicated medical marijuana portal at mmapplication.diversion.dea.gov. The portal includes self-registration, login, and intake routes, indicating applicants should expect to create credentials and then enter an application workflow.
4. Prepare proof of the state medical marijuana license in the form DEA requires. The final order explicitly requires applicants to submit the applicable DEA form (or forms) plus proof of state licensure.
5. File within 60 days of Federal Register publication if possible. That is the critical timing point in the order. Applicants who file within that window — which closes June 28 — may continue operating under their state license while DEA reviews the application.
6. Keep operations strictly within the scope of the state medical license. DEA registration cannot exceed that scope, and federal registration will be suspended automatically if the state license is suspended, revoked, or expires.
7. Do not assume adult-use activity is federally protected. The order is explicit that non-medical marijuana outside the covered categories remains Schedule I, and “those who handle such material remain subject to […] administrative, civil, and criminal sanctions.”
Verification and documentation: the knowns and unknowns
The final order clearly confirms one core application requirement: proof of a qualifying state medical marijuana license. It also makes clear DEA will evaluate the application under “public-interest” factors for the applicable registration category and under U.S. treaty obligations. But while the rule is explicit in many definitions, exactly what is meant by “public interest” remains vague
Also clear from the order is that DEA built several accommodations around existing state medical systems:
- State licenses count as conclusive evidence of state authorization.
- State-law security requirements are treated as sufficient.
- State-required records are to be accepted to the maximum extent federal law allows.
- State-authorized medical marijuana certifications can serve the dispensing function in place of a conventional federal controlled-substance prescription model, so long as specified identifying information is present.
The fine print: federal labeling and operational restrictions
The new portal is a genuine federal process, but it is not blanket cannabis amnesty.
The final order says any marijuana outside FDA-approved products and marijuana subject to a qualifying state medical marijuana license remains Schedule I. Hemp is unaffected. Synthetically derived THC is excluded. Unlicensed bulk marijuana remains subject to Schedule I controls. And the manufacturer provisions still include unusual federal treaty-compliance mechanisms, including a nominal DEA purchase-and-resale structure for crops.
The rule also stipulates that all products dispensed to patients must be labeled with “a clear, concise warning that it is a crime to transfer the drug to any person other than the patient.”
So while operators may reasonably see this as the first workable federal lane for parts of the medical market, it is still a tightly bounded lane.
The congressional wildcard: House GOP aims to stall further reform
House Republicans are moving an FY27 Commerce-Justice-Science appropriations bill this week, and the measure includes language that would bar the Department of Justice from using funds to reschedule marijuana more broadly: “Sec. 591. None of the funds appropriated under this Act or otherwise made available by this Act may be used to reschedule marijuana (as such term is defined in section 102 of the Controlled Substances Act (21 U.S.C. 802)) or to remove marijuana from the schedules established under section 202 of the Controlled Substances Act (21 U.S.C. 812).”
Even if that provision is struck from the marked-up final bill, the section signals congressional resistance remains active and could complicate assumptions about the next phase of federal reform.
That next phase already has been scheduled. A Notice of Proposed Hearing published in the Federal Register April 28 sets “a hearing with respect to the proposed rescheduling of marijuana into Schedule III of the Controlled Substances Act” for 9 a.m. June 29 at the DEA Hearing Facility in Washington, DC. Parties wishing to participate must provide written notice on or before May 28.
The takeaway
For operators, the practical takeaway is straightforward: Treat the DEA portal as an immediate compliance and planning development for medical businesses, but do not model your strategy around a clean, uncontested march to full Schedule III treatment for all cannabis.
Right now, the firms with the strongest case for action are state-licensed medical operators that can document their authority, fit themselves neatly into DEA’s new registration categories, and move quickly enough to preserve the 60-day pending-application protection.
